Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17825589 | 0.90 | ATM (0.40) | KMT2AHPGDGAACNR1CNR2 | |
| SCHEMBL6465472 | 0.84 | HPGD (0.38) | KDM4EKMT2APOLBHPGDGAA | |
| SCHEMBL17825591 | 0.82 | KIF11 (0.46) | CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL6464526 | 0.81 | HPGD (0.39) | KDM4EKMT2APOLBHPGDGAA | |
| SCHEMBL8843206 | 0.80 | HPGD (0.39) | KDM4EKMT2APOLBHPGDGAA | |
| SCHEMBL8842917 | 0.74 | HPGD (0.39) | KDM4EKMT2APOLBHPGDGAA | |
| SCHEMBL7912706 | 0.73 | KIF11 (0.41) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8843149 | 0.71 | KMT2A (0.40) | KDM4EKMT2APOLBHPGDGAA | |
| SCHEMBL5133757 | 0.71 | NFE2L2 (0.40) | KDM4EKMT2AGAAATMSMN1; SMN2 | |
| SCHEMBL24127770 | 0.70 | MTNR1A (0.41) | CNR1CNR2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4372091-A2 | COMPOSITIONS AND METHODS FOR EDITING NUCLEIC ACIDS IN CELLS UTILIZING OLIGONUCLEOTIDES | Woolf, Tod M. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3230445-B1 | COMPOSITIONS AND METHODS FOR EDITING NUCLEIC ACIDS IN CELLS UTILIZING OLIGONUCLEOTIDES | WOOLF TOD M (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20210395729-A1 | Compositions and methods for Editing Nucleic Acids in Cells Utilizing Oligonucleotides | ETAGEN PHARMA, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3230445-A2 | COMPOSITIONS AND METHODS FOR EDITING NUCLEIC ACIDS IN CELLS UTILIZING OLIGONUCLEOTIDES | Woolf, Tod M. (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094845-A2 | COMPOSITIONS AND METHODS FOR EDITING NUCLEIC ACIDS IN CELLS UTILIZING OLIGONUCLEOTIDES | WOOLF TOD M (US) | 2016-06-16 | — | — | WO | disclosed |